Treating Smoking in Cancer Patients: An Essential Component of Cancer Care
About the National Cancer Institute Monograph Series

The National Cancer Institute established the Tobacco Control Monograph series (formerly the Smoking and Tobacco Control Monograph series) in 1991. The series provides comprehensive scientific reviews of tobacco use, treatment, and prevention topics to inform the work of researchers, clinicians, and public health practitioners working to reduce cancer morbidity and mortality. All 23 Tobacco Control Monographs and their supplemental materials can be downloaded from cancercontrol.cancer.gov/monographs.

Citation

To cite this monograph in other works, please use the following format:

Contents

About the National Cancer Institute Monograph Series ............................................................. ii
Foreword ................................................................................................................................. xi
Acknowledgments .................................................................................................................... xiii
Table of Abbreviations and Acronyms .................................................................................... xx
Glossary .................................................................................................................................. xxi

Chapter 1. Introduction and Overview

Introduction ................................................................................................................................ 3
Smoking Among Cancer Patients and Survivors ...................................................................... 4
The Consequences of Continued Smoking After a Cancer Diagnosis ...................................... 5
Addressing Smoking Cessation in Cancer Care Settings ............................................................ 6
Purpose of the Monograph ........................................................................................................ 16
Preparation of the Monograph ................................................................................................. 18
Key Terminology and Concepts ............................................................................................... 18
The Multiple Phases of Smoking Cessation Treatment .............................................................. 19
Major Conclusions ................................................................................................................... 21
References ................................................................................................................................ 24

Chapter 2. Smoking in Patients with Cancer: Biological Factors

Introduction ................................................................................................................................ 3
Tobacco Smoke and Tumorigenesis .......................................................................................... 4
   Chemical Composition of Tobacco Smoke ............................................................................. 4
   Tobacco Smoke: DNA Damage ............................................................................................... 5
   Tobacco Smoke: Mutational Burden ..................................................................................... 6
   Tobacco Smoke: Mutational Signatures ................................................................................. 6
   Tobacco Smoke: Cancer Driver Genes ................................................................................. 7
   Tobacco Smoke: Epigenetic Changes ................................................................................... 7
Biological Characteristics of Lung Cancers in Smokers and Never-Smokers ......................... 7
   Lung Cancer: Driver Genes .................................................................................................. 8
   Lung Cancer: Mutational Burden ......................................................................................... 8
   Lung Cancer: Epigenetic Modifications ............................................................................... 9
   Lung Cancer: Variation in Gene Expression ......................................................................... 9
   Therapeutic Implications of Molecular Differences in Lung Cancers ................................ 10
The Effects of Tobacco Smoke Exposure on Cancer Cells ...................................................... 10
   DNA Damage ..................................................................................................................... 11
   Changes in Gene Expression ............................................................................................... 11
   Alteration of Cell Cycle Control ......................................................................................... 11
   Promotion of Epithelial-Mesenchymal Transition Associated With Metastasis ................ 11
   Promotion of Angiogenesis ................................................................................................. 12
   Alterations Within the Tumor Microenvironment ............................................................... 12
   Promotion of Stem Cell–Like Properties ............................................................................. 12
   Inhibition of Response to Chemotherapeutic Agents ......................................................... 12
Summary ................................................................................................................................ 13
## Contents

Conclusions .................................................................................................................. 13  
References .................................................................................................................. 14

### Chapter 3. Treating Tobacco Use and Dependence in Cancer Populations

Introduction .................................................................................................................. 4  
Motivation to Quit .......................................................................................................... 5  
Element of Effective Smoking Cessation Treatments ...................................................... 6  
   Neurobiological and Behavioral-Motivational Dimensions of Cigarette Smoking:  
      Relevance to Treatment .......................................................................................... 7  
      Neurobiological Dimensions of Cigarette Smoking ................................................. 7  
      Behavioral-Motivational Dimensions of Cigarette Smoking .................................. 8  
      Summary: Neurobiological and Behavioral-Motivational Dimensions of Cigarette  
      Smoking ................................................................................................................. 8  
Smoking Cessation Treatments in the General Population ............................................. 9  
   Approach .................................................................................................................. 9  
   Medications for Smoking Cessation ......................................................................... 9  
   Behavioral Interventions for Smoking Cessation .................................................... 15  
   Beyond In-Person Counseling: Telephone, Telehealth, and Digital Approaches for  
   Smoking Cessation .................................................................................................... 22  
Smoking Cessation Treatments Among Patients With Cancer ...................................... 29  
   Medications for Smoking Cessation Among Patients With Cancer ......................... 30  
   Behavioral Interventions for Smoking Cessation Among Patients With Cancer ........ 35  
   Relapse Prevention and Chronic Care for Cancer Populations ................................ 41  
Special Considerations and Barriers Concerning Smoking Cessation Treatment in Cancer  
   Care Settings ........................................................................................................... 42  
   Patient-Level Barriers to Treating Tobacco Use in Cancer Care Settings .................. 42  
      Psychiatric Comorbidity ......................................................................................... 42  
      Oncology Treatment–Related Challenges ............................................................... 43  
      Physical Concerns .................................................................................................. 44  
      Psychological Aspects ............................................................................................ 44  
      Treatment Engagement and Adherence .................................................................. 44  
   Clinician-Level Barriers to Treating Tobacco Use in Cancer Care Settings ............... 46  
      Leveraging the Opportunity for Intervention ....................................................... 46  
      Barriers to Intervention and Strategies to Overcome Them .................................... 46  
      Changing Clinician Approaches to Smoking Cessation Treatment ....................... 47  
   Systems-Level Barriers to Treating Tobacco Use in Cancer Care Settings ............... 48  
      Summary: Special Considerations and Barriers Concerning Smoking Cessation  
      Treatment in Cancer Care Settings ........................................................................ 48  
Special Topics in the Treatment of Smoking in Patients With Cancer  
   Addressing Motivation to Quit .................................................................................. 49  
   Relevance of Pharmacogenetic Intervention: Steps Toward Personalized Medicine .... 49  
   Treatment Effectiveness and Access Across Different Populations ......................... 51  
The Use of Electronic Nicotine Delivery Systems (ENDS) in Patients With Cancer  
   Prevalence of ENDS Use ......................................................................................... 52  
   Health Effects of ENDS ........................................................................................... 52
ENDS Use and Cessation From Cigarettes in the General Population.......................... 53
Randomized Controlled Trials ................................................................................. 54
ENDS Use and Cessation From Cigarettes in Cancer Populations ....................... 56
Published Guidelines on ENDS Use Among Patients With Cancer ....................... 57
Summary: The Use of ENDS in Patients With Cancer ........................................... 57
Summary .................................................................................................................... 58
Conclusions ................................................................................................................. 59
References .................................................................................................................... 60

Chapter 4. Implementing Smoking Cessation Treatment Programs in Cancer Care Settings: Challenges, Strategies, Innovations, and Models of Care

The Importance of a Systematic Approach to Treating Tobacco Use in Cancer Care Settings ............................................................................................................................................. 5
Introduction ................................................................................................................... 5
Application of the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) Evaluation Framework ............................................................................................................................................. 8
Reach..................................................................................................................................................... 9
Enhancing Reach via Leveraging the Electronic Health Record (EHR) .................... 9
Enhancing Reach via Use of Clinical Referral Models Including “Ask, Advise, Refer” (AAR) and “Ask, Advise, Connect” (AAC) ..................................................................................................................... 11
Treatment Extender: State Quitlines ............................................................................ 11
Treatment Extenders: National Cancer Institute's (NCI) SmokefreeTXT ..................... 16
Utilizing Interactive Voice Response (IVR) Systems ............................................... 16
Opt-Out Versus Opt-In Models of Smoking Cessation Treatment Delivery .......... 17
Using Telehealth ........................................................................................................... 18
Summary: Reach ............................................................................................................. 18
Effectiveness ................................................................................................................... 19
Summary: Effectiveness .................................................................................................. 20
Adoption ............................................................................................................................. 20
Payment Models, Quality Metrics, and Regulation ................................................... 21
Legislative Action ........................................................................................................... 24
Summary: Adoption ....................................................................................................... 25
Implementation ................................................................................................................... 26
Summary: Implementation .............................................................................................. 26
Maintenance ..................................................................................................................... 26
Secure Support From Health Care System Leadership ............................................ 27
Integrate Tobacco Screening and Treatment Strategies Into Clinical Workflows ........ 27
Leverage EHRs .............................................................................................................. 28
Leveraging Tobacco-Relevant Quality Metrics, Payment Models, and Regulatory Policies ................................................................................................................................. 28
Summary: Maintenance ................................................................................................. 28
Assessing and Verifying Tobacco Use Status ............................................................. 29
Challenges to Implementing Smoking Cessation Treatment in Cancer Care Settings at the Patient, Clinician, and Health Care System Levels ........................................................................................................... 31
Patient-Level Barriers to Delivering Smoking Cessation Treatment in Cancer Care Settings ........................................................................................................................................... 33
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sociodemographic Differences in Smoking Rates</td>
<td>33</td>
</tr>
<tr>
<td>Knowledge of Risks of Smoking and Benefits of Quitting</td>
<td>34</td>
</tr>
<tr>
<td>Motivation and Confidence to Quit</td>
<td>35</td>
</tr>
<tr>
<td>Psychological Distress</td>
<td>35</td>
</tr>
<tr>
<td>Coping</td>
<td>36</td>
</tr>
<tr>
<td>Summary: Patient-Level Barriers</td>
<td>36</td>
</tr>
<tr>
<td>Clinician-Level Barriers to Delivering Smoking Cessation Treatment in Cancer Care Settings</td>
<td>36</td>
</tr>
<tr>
<td>Lack of Smoking Cessation Knowledge and Training</td>
<td>36</td>
</tr>
<tr>
<td>Clinician Perceptions of Patients With Cancer</td>
<td>38</td>
</tr>
<tr>
<td>Summary: Clinician-Level Barriers</td>
<td>40</td>
</tr>
<tr>
<td>Health Care System–Level Barriers to Delivering Smoking Cessation Treatment in Cancer Care Settings</td>
<td>40</td>
</tr>
<tr>
<td>Institutional Commitment and Accountability</td>
<td>40</td>
</tr>
<tr>
<td>Limitations of Clinician Time and Referral Options</td>
<td>41</td>
</tr>
<tr>
<td>Funding and Reimbursement for Smoking Cessation Treatment Programs</td>
<td>42</td>
</tr>
<tr>
<td>Summary: Health Care System–Level Barriers</td>
<td>43</td>
</tr>
<tr>
<td>A Systems Approach to Providing Smoking Cessation Treatment Across the Cancer Care Continuum</td>
<td>43</td>
</tr>
<tr>
<td>Smoking Cessation Treatment at Cancer Screening</td>
<td>44</td>
</tr>
<tr>
<td>Eligibility, Guidelines, and Policy for Lung Cancer Screening (LCS)</td>
<td>45</td>
</tr>
<tr>
<td>Impact of LCS on Smoking</td>
<td>45</td>
</tr>
<tr>
<td>Enhancing Smoking Cessation Treatment Reach and Effectiveness in the Context of LCS</td>
<td>45</td>
</tr>
<tr>
<td>Cancer Diagnosis</td>
<td>47</td>
</tr>
<tr>
<td>Cancer Treatment</td>
<td>48</td>
</tr>
<tr>
<td>Smoking Cessation Treatment for Patients With Advanced Cancer</td>
<td>48</td>
</tr>
<tr>
<td>Post-Treatment and Long-Term Survivorship</td>
<td>49</td>
</tr>
<tr>
<td>Summary: Cessation Across the Cancer Care Continuum</td>
<td>50</td>
</tr>
<tr>
<td>The Economic Rationale for Implementing Smoking Cessation Treatment in Cancer Care</td>
<td>50</td>
</tr>
<tr>
<td>Incremental Costs Associated With a Smoking History Among Patients With Cancer</td>
<td>50</td>
</tr>
<tr>
<td>Cost-Effectiveness of Smoking Cessation Treatment for Individuals With Cancer</td>
<td>52</td>
</tr>
<tr>
<td>Cost-Effectiveness of Smoking Cessation Treatment in the Context of LCS</td>
<td>53</td>
</tr>
<tr>
<td>Summary: Economic Outcomes Related to Smoking in Patients With Cancer</td>
<td>53</td>
</tr>
<tr>
<td>Disseminating and Implementing Tobacco Cessation Treatment in Cancer Care Settings:</td>
<td>54</td>
</tr>
<tr>
<td>The NCI Cancer Center Cessation Initiative (C3I)</td>
<td>57</td>
</tr>
<tr>
<td>Models of Tobacco Cessation Treatment Employed by C3I Sites</td>
<td>57</td>
</tr>
<tr>
<td>Point-of-Care Treatment Models</td>
<td>59</td>
</tr>
<tr>
<td>Internal Referral Treatment Models</td>
<td>59</td>
</tr>
<tr>
<td>External Referral Treatment Models</td>
<td>59</td>
</tr>
<tr>
<td>Lessons Learned From Implementation of C3I</td>
<td>60</td>
</tr>
<tr>
<td>Summary</td>
<td>62</td>
</tr>
<tr>
<td>Conclusions</td>
<td>63</td>
</tr>
<tr>
<td>References</td>
<td>64</td>
</tr>
</tbody>
</table>
Chapter 5. Addressing Smoking in Medically Underserved and Vulnerable Cancer Populations

Introduction ..................................................................................................................................... 4
The Socioecological Model ........................................................................................................ 5
Combinatorial Effects on Vulnerabilities ................................................................................. 6
Stigma in Medically Underserved and Vulnerable Populations ............................................... 6
Prevalence and Trends in Smoking: Relevance to Medically Underserved and Vulnerable Populations With Cancer ........................................................................................ 7
Heterogeneity Among Medically Underserved and Vulnerable Populations ......................... 10
Cancer Burden .............................................................................................................................. 10
Factors Associated With Cancer Burden ................................................................................ 12
Summary: Cancer Burden ....................................................................................................... 12
Smoking Cessation Treatment for Medically Underserved and Vulnerable Populations in the Clinical Cancer Care Context ................................................................................................. 12
Smoking Among Socioeconomically Disadvantaged Populations With Cancer .................. 12
Epidemiology ............................................................................................................................. 12
Smoking Cessation .................................................................................................................. 13
Barriers to Smoking Cessation ............................................................................................... 13
Summary: Smoking Among Socioeconomically Disadvantaged Populations With Cancer ................................................................................................................................. 14
Smoking Among Racial and Ethnic Minority Populations With Cancer ............................... 14
Epidemiology .................................................................................................................................. 14
Smoking Cessation ................................................................................................................ 16
Barriers to Smoking Cessation ............................................................................................... 18
Summary: Smoking Among Racial and Ethnic Minority Populations With Cancer ............ 20
Smoking Among Rural Populations With Cancer .................................................................. 20
Epidemiology .................................................................................................................................. 20
Smoking Cessation ................................................................................................................ 20
Barriers to Smoking Cessation ............................................................................................... 21
Summary: Smoking Among Rural Populations with Cancer ............................................ 22
Smoking Among Sexual and Gender Minority (SGM) Populations with Cancer ............... 22
Epidemiology ............................................................................................................................. 22
Smoking Cessation ................................................................................................................ 23
Barriers to Smoking Cessation ............................................................................................... 24
Summary: Smoking Among SGM Populations With Cancer ............................................ 25
Smoking Among People With Co-Occurring Substance Use Disorders and Cancer .......... 25
Epidemiology .................................................................................................................................. 25
Smoking Cessation ................................................................................................................ 30
Barriers to Smoking Cessation ............................................................................................... 31
Summary: Smoking Among People With Co-Occurring Substance Use Disorders and Cancer ....... 32
Chapter 6. Monograph Conclusions and Future Research Directions

Introduction ..................................................................................................................................... 3
Major Conclusions ......................................................................................................................... 3
Chapter Summaries and Conclusions ........................................................................................... 5
Chapter 1: Introduction and Overview ..................................................................................... 5
Chapter 2: Smoking in Patients With Cancer: Biological Factors ............................................ 5
Conclusions ................................................................................................................................... 5
Chapter 3: Treating Tobacco Use and Dependence in Cancer Populations ............................. 5
Conclusions ................................................................................................................................. 5
Chapter 4: Implementing Smoking Cessation Treatment Programs in Cancer Care Settings: Challenges, Strategies, Innovations, and Models of Care ......................................... 6
Conclusions ................................................................................................................................. 7
Chapter 5: Addressing Smoking in Medically Underserved and Vulnerable Cancer Populations ................................................................................................................................ 8
Conclusions ................................................................................................................................. 8
Future Research Directions ............................................................................................................. 8
Clarifying the Effects of Continued Smoking and Smoking Cessation Treatment on Cancer Outcomes ................................................................................................................................. 10
Assessing the Economic Effects of Continued Smoking and Cessation After a Cancer Diagnosis ................................................................................................................................. 10
Achieving Better Tobacco Use Assessment in Cancer Care ....................................................... 11
Addressing Barriers to the Implementation of Effective Treatment of Tobacco Use in Cancer Care ........................................................................................................................................ 11
Understanding the Effects of New Tobacco Products and Other Drug Use in Patients With Cancer ........................................................................................................................................ 13
Optimizing Smoking Cessation Treatment for Medically Underserved and Vulnerable Populations With Cancer ................................................................................................................. 13
NCI Initiatives to Support Implementation of Smoking Cessation Treatment in Cancer Care and Screening Settings ..................................................................................................................... 15
Cancer Center Cessation Initiative (C3I) ................................................................................ 15
Smoking Cessation at Lung Examination (SCALE) Collaboration ....................................... 16
Conclusion .................................................................................................................................... 16
References ...................................................................................................................................... 18
Figures and Tables

Figures
Figure 1.1 Opportunities for Smoking Intervention Across the Cancer Care Continuum .......... 7
Figure 1.2 Phases of Smoking Treatment................................................................. 20
Figure 2.1 Major Pathways of Cancer Causation by Cigarette Smoking ...................... 5
Figure 3.1 Smokefree.gov Initiative Digital Interventions ......................................... 25
Figure 3.2 Examples of Patient-, Clinician-, and Systems-Level Barriers to the Use of Smoking Cessation Treatment in Cancer Care Settings................................. 42
Figure 4.1 Typical EHR-Guided Staff Workflow for eReferral of a Patient who Smokes From a Clinical Setting to a State Quitline or SmokefreeTXT ......................... 13
Figure 4.2 Joint Commission Tobacco Cessation Measures ..................................... 23
Figure 4.3 Smoking Cessation Treatment Across the Cancer Care Continuum, From Screening to Long-Term Survivorship......................................................... 44
Figure 4.4 National Cancer Institute (NCI) Cancer Center Cessation Initiative (C3I) Sites ................................................................. 55
Figure 4.5 Elements of Exemplar Tobacco Cessation Treatment Programs: Three Models Used Successfully in Cancer Care Settings ........................................ 58
Figure 4.6 Methods Used by Cancer Center Cessation Initiative (C3I) Sites to Track Program Reach and Effectiveness............................................................. 62
Figure 5.1 Current Cigarette Smoking Prevalence and Quitting by Past-Year Substance Use Disorder Status and Past-Year Cancer Diagnosis Among U.S. Adults Aged 18 and Older, 2015–2018 ......................................................... 27

Tables
Table 1.1 Current and Former Smoking Among Adult Cancer Survivors, 2020 .............. 4
Table 1.2 Findings From the 2014 and 2020 Surgeon General’s Reports ................. 8
Table 1.3 Studies That Compare All-Cause Mortality in Patients Who Quit Smoking After a Cancer Diagnosis With Patients Who Continued After Diagnosis (2017–2021) ................................................................. 10
Table 1.4 Summary of Recommendations for Addressing Tobacco Use Among Cancer Patients ................................................................. 13
Table 1.5 Monograph Terminology ........................................................................... 18
Table 2.1 Key Characteristics of Carcinogens .......................................................... 4
Table 3.1 Findings Regarding Interventions for Smoking Cessation and Treatments for Nicotine Dependence From the 2020 Surgeon General’s Report on Smoking Cessation ........................................................................ 7
Table 3.2 Effectiveness and Abstinence Rates for Various Medications and Medication Combinations Compared to Placebo at 6-Months Post-quit ......................... 10
Table 3.3 Odds of Smoking Cessation Using Medications ........................................ 15
Table 3.4  Odds of Smoking Cessation Using Behavioral Interventions .............................. 16
Table 3.5  Elements of Brief Tobacco-Cessation Counseling Based on the PHS Clinical Practice Guideline, *Treatting Tobacco Use and Dependence: 2008 Update* .......... 17
Table 3.6  Studies of Smoking Cessation Interventions Among Patients With Cancer .......... 32

Table 4.1  Selected Guidelines and Recommendations from Clinical and Research Organizations for Addressing Tobacco Use in Cancer Care Settings .................. 6
Table 4.2  Consensus Assessment Instrument for Tobacco Use in Oncology (C-TUQ, Selected Items) ........................................................................................................ 29
Table 4.3  Challenges to Implementing Smoking Cessation Treatment in Cancer Care Settings at the Patient, Clinician, and Health Care System Levels ................. 31
Table 4.4  Guidance from the Association for the Treatment of Tobacco Use and Dependence (ATTUD)/the Society for Research on Nicotine and Tobacco (SRNT) Regarding Smoking Cessation Treatment and Smoking Cessation Within Lung Cancer Screening Programs ................................................. 47

Table 5.1  Prevalence of Current Cigarette Smoking Among U.S. Adults Aged 18 and Older, by Sex, Race and Ethnicity, Poverty Status, Income, Educational Attainment, and Sexual Orientation, 1994–2020 .............................................................. 8
Table 5.2  Substance Use Disorders Among U.S. Adults Aged 18 and Older With and Without a Past-Year Cancer Diagnosis, 2015–2018 .................................................. 28
Table 6.1  Summary of Research Needs .................................................................................... 9
Foreword

The National Cancer Institute’s (NCI’s) role in tobacco control has been long, broad, and deep. The uniqueness of NCI’s role is due, in part, to the National Cancer Act of 1971, which granted special authorities and responsibilities to the institute, including a determination that NCI’s director be appointed directly by the President—the only institute director at the National Institutes of Health with this special status.

The recognition of the 50th anniversary of the National Cancer Act in 2021 illustrated that the dissemination mission assigned by Congress to NCI continues to be manifested in a variety of ways. In the case of tobacco control, the Tobacco Control Monograph series is one key vehicle that NCI uses to disseminate research evidence to a global audience. The monograph series leverages the scientific independence afforded by NCI’s authorities with the institute’s firmly established credibility throughout the international biomedical and public health communities. In an era plagued by rampant misinformation, the value of authoritative, peer-reviewed summaries of the research literature has never been higher. The rigorously transparent, data-driven, and self-corrective nature of the scientific enterprise enables both medicine and public health to evolve and adapt to ever-changing threats, but only if the latest scientific evidence is provided in a clear and actionable manner to those in a position to use it. This monograph seeks to fulfill that goal by providing clinicians with the latest knowledge concerning smoking among their patients, while providing scientists with clear descriptions of research gaps remaining to be filled.

This monograph describes a variety of research efforts conducted over a span of decades that have sought to describe, explain, and address the nature and consequences of smoking among patients with cancer. Long-standing, recalcitrant problems in medicine and public health can persist for many years until a catalyst (often in the form of a person or people) meets a special opportunity (often in the form of new funding). In the case of tobacco use among patients with cancer, the catalysts were two members of NCI’s advisory boards, Karen Emmons, Ph.D., and Graham Colditz, M.D., Dr.P.H. The opportunity was the Beau Biden Cancer MoonshotSM, a special 7-year initiative supported by the 21st Century Cures Act, which was passed by Congress in 2016. During a discussion at a meeting of the NCI advisory boards, Emmons and Colditz suggested that addressing the lack of tobacco use assessment and treatment among all patients treated for cancer at NCI-Designated Cancer Centers would be a worthy goal of the Cancer Moonshot. This author, then serving as the Director of NCI’s Division of Cancer Control and Population Sciences, was charged by the then-Acting NCI Director, Douglas R. Lowy, M.D., to propose a major effort to support the enhancement and evaluation of research-based smoking cessation programs within NCI-Designated Cancer Centers. This led to NCI’s funding of the Cancer Center Cessation Initiative (C3I), the largest-ever effort to evaluate and improve the quality of care for patients with cancer who use tobacco products.

Although C3I is only one of many research initiatives discussed in this monograph, its launch led to a broader revitalization of NCI’s efforts concerning tobacco use among patients with cancer. This monograph is an important component of this broader set of efforts, that have included the strengthening of collaborations with other agencies and organizations; sustained support for Smokefree.gov, the federal government’s primary digital health resource for tobacco cessation; and expanded support through research grants to study tobacco cessation program implementation in clinical settings.
The slow rate of progress in providing all patients with cancer with high-quality smoking cessation services is the result of a complex set of barriers at the level of the practitioner, the health care organization, the payer, and the policymaker. Both institutional and sociological barriers are discussed within the chapters that follow. However, it is clear that the lack of financial incentives (i.e., low reimbursement rates for these services) and an insufficient appreciation of the importance of smoking cessation among clinicians and their service line managers have played a role. We hope that the compilation of evidence provided by this monograph will serve as an important catalyst to action through enhancements in payment incentives, professional training, the structure of healthcare systems, and through underscoring the moral imperative of providing the highest quality cancer care to every patient. It is never too late to quit, nor is it too late for all of us to complete the task of enabling every patient with cancer to rid themselves of the most devastating carcinogen known to humanity.

Robert T. Croyle, Ph.D.
Former Director
Division of Cancer Control and Population Sciences
National Cancer Institute
Acknowledgments

Scientific Editorial Committee (SEC)

Chairs

Timothy Baker, Ph.D.
Director of Research
University of Wisconsin Center for Tobacco Research and Intervention
University of Wisconsin-Madison
Madison, Wisconsin

Michael Fiore, M.D., M.P.H., M.B.A.
Director
University of Wisconsin Center for Tobacco Research and Intervention
University of Wisconsin-Madison
Madison, Wisconsin

Gordon Willis, Ph.D.
Program Director
Tobacco Control Research Branch
Behavioral Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Members

Monica Webb Hooper, Ph.D.
Deputy Director
National Institute on Minority Health and Health Disparities
National Institutes of Health
Bethesda, Maryland

Anne Joseph, M.D., M.P.H.
Wexler Professor of Medicine
Division of General Internal Medicine
Department of Medicine
University of Minnesota Medical School
Minneapolis, Minnesota

Managing Editor

Kristen Mangold, M.S.W.
Public Health Advisor
Tobacco Control Research Branch
Behavioral Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Chapter Leads

Lisa A. Peterson, Ph.D.
Professor, Division of Environmental Health Sciences
Program Co-Leader, Carcinogenesis and Chemoprevention, Masonic Cancer Center
School of Public Health
University of Minnesota
Minneapolis, Minnesota

Robert A. Schnoll, Ph.D.
Director, Center for Interdisciplinary Research on Nicotine Addiction, Department of Psychiatry, Perelman School of Medicine
Professor, Department of Psychiatry, Perelman School of Medicine
Associate Director for Population Science, Abramson Cancer Center
Senior Fellow, Center for Public Health Initiatives
University of Pennsylvania
Philadelphia, Pennsylvania

Vani N. Simmons, Ph.D.
Co-Director, Tobacco Research and Intervention Program
Senior Member, Department of Health Outcomes and Behavior
Moffitt Cancer Center
Tampa, Florida

Hilary A. Tindle, M.D., M.P.H.
Associate Professor of Medicine, School of Medicine and Vanderbilt Ingram Cancer Center
William Anderson Spickard Jr., M.D., Chair in Medicine
Founding Director of ViTAL, the Vanderbilt Center for Tobacco, Addiction and Lifestyle
Vanderbilt University
Nashville, Tennessee

Graham Warren, M.D., Ph.D.
Professor and Mary M. Gilbreth Endowed Chair of Clinical Oncology
Vice Chairman for Research in Radiation Oncology
Department of Radiation Oncology
Department of Cell and Molecular Pharmacology and Experimental Therapeutics
Hollings Cancer Center
Medical University of South Carolina
Charleston, South Carolina
Contributors

Rob Adsit, M.Ed.
Director of Education and Outreach
Center for Tobacco Research and Intervention
School of Medicine and Public Health
University of Wisconsin-Madison
Madison, Wisconsin

Steven L. Bernstein, M.D.
Chief Research Officer
Dartmouth-Hitchcock Medical Center
Senior Associate Dean for Clinical and Translational Research
Geisel School of Medicine at Dartmouth
Director, C. Everett Koop Institute
Professor of Emergency Medicine
Lebanon, New Hampshire

Paul M. Cinciripini, Ph.D.
Professor and Chair, Department of Behavioral Science
Division of Cancer Prevention and Population Sciences
University of Texas
MD Anderson Cancer Center
Houston, Texas

Heather D’Angelo, Ph.D., M.H.S.
Program Director
Health Communication and Informatics Research Branch
Behavioral Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Nicole Senft Everson, Ph.D.
Program Director
Health Communication and Informatics Research Branch
Behavioral Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Michael T. Halpern, M.D., Ph.D., M.P.H.
Medical Officer
Healthcare Assessment Research Branch
Healthcare Delivery Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Brian L. Hitsman, Ph.D.
Associate Professor of Preventive Medicine
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Frank T. Leone, M.D., M.S.
Professor, Medicine
Director, Comprehensive Smoking Treatment Programs
University of Pennsylvania, Perelman School of Medicine
Philadelphia, Pennsylvania

Margaret Mayer, Ph.D., M.P.H.
Program Director
Tobacco Control Research Branch
Behavioral Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

LaTrice Montgomery, Ph.D.
Research Associate Professor
Psychiatry and Behavioral Neuroscience
University of Cincinnati, College of Medicine
Cincinnati, Ohio

Mark Parascandola, Ph.D., M.P.H.
Chief, Research and Training Branch
Center for Global Health
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Jamie S. Ostroff, Ph.D.
Chief, Behavioral Sciences Service and Vice Chair of Research
Department of Psychiatry and Behavioral Sciences
Memorial Sloan Kettering Cancer Center
Professor of Population Health Sciences
Weill Medical College of Cornell University
New York, New York

Ramzi G. Salloum, Ph.D.
Associate Professor, Health Outcomes and Biomedical Informatics, College of Medicine
University of Florida
Gainesville, Florida

Christine E. Sheffer, Ph.D.
Professor of Oncology, Department of Health Behavior
Roswell Park Comprehensive Cancer Institute
Buffalo, New York
Jamie L. Studts, Ph.D.
Professor
Division of Medical Oncology
Department of Medicine
University of Colorado School of Medicine
Co-Leader of Cancer Prevention and Control
University of Colorado Cancer Center
Aurora, Colorado

Reviewers

Brian S. Armour, Ph.D.
Associate Director for Science
Office on Smoking and Health
Centers for Disease Control and Prevention
Atlanta, Georgia

Julia T. Arnold, Ph.D., M.S.
Program Director
Translational Research Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

David Berrigan, Ph.D., M.P.H.
Program Director
Health Behaviors Research Program
Behavioral Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Kelly D. Blake, Sc.D.
Program Director
Health Communication and Informatics Research Branch
Behavioral Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Michele Bloch, M.D., Ph.D.
Chief, Tobacco Control Research Branch
Behavioral Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Thomas H. Brandon, Ph.D.
Department Chair and Program Leader, Health Outcomes and Behavior
Moffitt Distinguished Scholar
Director, Tobacco Research & Intervention Program
Moffitt Cancer Center
Professor, University of South Florida Departments of Psychology and Oncologic Sciences
Tampa, Florida

Alexandra R. Budenz, Dr.P.H., M.A.
Social Scientist
Office of Health Communication and Education Center for Tobacco Products
Food and Drug Administration
Silver Spring, Maryland

Priscilla Callahan-Lyon, M.D.
Senior Science Advisor
Office of the Center Director
Center for Tobacco Products
Food and Drug Administration
Silver Spring, Maryland

Matthew J. Carpenter, Ph.D.
Professor, College of Medicine, Department of Psychiatry and Behavioral Sciences
Co-Leader, Cancer Control Program
Hollings Cancer Center
Medical University of South Carolina
Charleston, South Carolina

Frank J. Chaloupka, Ph.D.
Distinguished Professor Emeritus
University of Illinois Chicago
Chicago, Illinois

David Chambers, DPhil
Deputy Director for Implementation Science
Office of the Director
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Srikumar Chellappan, Ph.D.
Moffitt Distinguished Scholar, Professor, and Chair
Department of Tumor Biology
Moffitt Cancer Center
Tampa, Florida
Acknowledgments

Joseph T. Ciccolo, Ph.D.
Program Director
Tobacco Control Research Branch
Behavioral Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

JoyAnn (Rohan) Courtney, Ph.D.
Health Scientist Administrator
Office of Disease Prevention
National Institutes of Health
Bethesda, Maryland

Elizabeth A. Courtney-Long, M.A., M.S.P.H.
Deputy Associate Director for Science
Office on Smoking and Health
Centers for Disease Control and Prevention
Atlanta, Georgia

K. Michael Cummings, Ph.D., M.P.H.
Professor, College of Medicine, Department of
Psychiatry and Behavioral Sciences
Medical University of South Carolina
Co-Leader Tobacco Research Program
Hollings Cancer Center
Charleston, South Carolina

Carolyn Dresler, M.D., M.P.A.
Volunteer, Action on Smoking and Health
Thoracic Surgical Oncologist, Retired
Western Colorado

Kristie Foley, Ph.D., M.S.
Professor and Chair, Department of
Implementation Science
Acting Senior Associate Dean for Research
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Neal D. Freedman, Ph.D., M.P.H.
Senior Investigator
Metabolic Epidemiology Branch
Division of Cancer Epidemiology and Genetics
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Kya Grooms, Ph.D., M.P.H.
ORISE Post-Doctoral Fellow
Oak Ridge Institute for Science and Education
Office on Smoking and Health
Centers for Disease Control & Prevention
Atlanta, Georgia

Jaimee Heffner, Ph.D.
Associate Professor, Cancer Prevention Program
Public Health Sciences Division
Fred Hutchinson Cancer Research Center
Seattle, Washington

Nadia Howlader, Ph.D., M.S.
Program Director and Cancer Epidemiologist
Data Analytics Branch
Surveillance Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Leah Hubbard, Ph.D.
Program Director, Brain, Skin, and Head &
Neck/Thyroid Specialized Programs of Research
Excellence Translational Research Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Maki Inoue-Choi, Ph.D., M.S., R.D.
Staff Scientist
Metabolic Epidemiology Branch
Division of Cancer Epidemiology and Genetics
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Paul Jacobsen, Ph.D.
Associate Director
Healthcare Delivery Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Ron Johnson, Ph.D.
Program Director
DNA and Chromosome Aberrations Branch
Division of Cancer Biology
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

William M. P. Klein, Ph.D.
Associate Director
Behavioral Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland
Acknowledgments

Kimber P. Richter, Ph.D., M.P.H., NCTTP
Director, UKanQuit at the University of Kansas Hospital
Professor, Population Health
Co-founder, University of Kansas Tobacco Treatment Specialist Training Program
University of Kansas School of Medicine
Kansas City, Kansas

Erin Rogers, Dr.P.H., M.P.H.
Assistant Professor
Department of Population Health
NYU Grossman School of Medicine
NYU Langone Health
New York, New York

Isabel C. Scarinci, Ph.D., M.P.H.
Professor
Vice-Chair for Global and Rural Health Department of Obstetrics and Gynecology
Heersink School of Medicine
Senior Advisor for Globalization and Cancer O’Neal Comprehensive Cancer Center
University of Alabama at Birmingham
Birmingham, Alabama

Peter G. Shields, M.D.
Deputy Director, Comprehensive Cancer Center
Professor, Epidemiology
College of Public Health
The Ohio State University
Columbus, Ohio

Eva Szabo, M.D.
Chief, Lung and Upper Aerodigestive Cancer Research Group
Division of Cancer Prevention
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Kathryn L. Taylor, Ph.D.
Professor, Department of Oncology
Cancer Prevention and Control Program
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, D.C.

Cheryll C. Thomas, M.S.P.H.
Deputy Associate Director for Science
Division of Cancer Prevention and Control Centers for Disease Control and Prevention
Atlanta, Georgia

Randi Tolsty, M.S.Ed.
Public Health Analyst
Office on Smoking and Health
Centers for Disease Control and Prevention
Atlanta, Georgia

Emily S. Tonorezos, M.D., M.P.H.
Director
Office of Cancer Survivorship
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Peter Ujhazy, M.D., Ph.D.
Deputy Associate Director
Translational Research Program
Division of Cancer Treatment and Diagnosis
National Cancer Institute
National Institutes of Health
Bethesda, Maryland

Brenna VanFrank, M.D., M.S.P.H.
Medical Officer
Office on Smoking and Health
Centers for Disease Control and Prevention
Atlanta, Georgia

Robert E. Vollinger, Jr., Dr.P.H., M.S.P.H.
Senior Policy Analyst
Office on Smoking and Health
Centers for Disease Control and Prevention
Washington, D.C.

Editorial and Publication Support

Laura Baker, M.P.H.
Senior Public Health Associate
The Bizzell Group
New Carrollton, Maryland

Dana Chomenko, M.A., PMP
Vice President, Public Health Research and Evaluation
BLH Technologies, Inc.
Rockville, Maryland

Megan Keil, M.P.H.
Public Health Associate
The Bizzell Group
New Carrollton, Maryland

Cailey Muñana, M.P.H.
Public Health Associate
The Bizzell Group
New Carrollton, Maryland
Jenny Twesten, M.P.H.
Managing Director, Health Research
The Bizzell Group
New Carrollton, Maryland

K. Ceres Wright, M.A.
Scientific Publications Manager/Writer–Editor
The Bizzell Group
New Carrollton, Maryland

The team acknowledges the editing, design, and project management support from the following:

Lisa Adams, BLH Technologies, Inc.
Pam Grimes, BLH Technologies, Inc.
Terry Head, BLH Technologies, Inc.
Sarah Ashley Jolly, BLH Technologies, Inc.
Susan Long, The Bizzell Group
Jolie A. Mandelbaum, BLH Technologies, Inc.
Srila Sen, The Bizzell Group
Stephanie Siekierka, BLH Technologies, Inc.
### Table of Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation/Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AACR</td>
<td>American Association for Cancer Research</td>
</tr>
<tr>
<td>ASCO</td>
<td>American Society of Clinical Oncology</td>
</tr>
<tr>
<td>BRFSS</td>
<td>Behavioral Risk Factor Surveillance System</td>
</tr>
<tr>
<td>C3I</td>
<td>Cancer Center Cessation Initiative</td>
</tr>
<tr>
<td>CBT</td>
<td>Cognitive behavioral therapy</td>
</tr>
<tr>
<td>CDC</td>
<td>U.S. Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>EHR</td>
<td>Electronic health record</td>
</tr>
<tr>
<td>ENDS</td>
<td>Electronic nicotine delivery systems</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>IASLC</td>
<td>International Association for the Study of Lung Cancer</td>
</tr>
<tr>
<td>NCCN</td>
<td>National Comprehensive Cancer Network</td>
</tr>
<tr>
<td>NCI</td>
<td>U.S. National Cancer Institute</td>
</tr>
<tr>
<td>NHIS</td>
<td>National Health Interview Survey</td>
</tr>
<tr>
<td>NRT</td>
<td>Nicotine replacement therapy</td>
</tr>
<tr>
<td>USPSTF</td>
<td>U.S. Preventive Services Task Force</td>
</tr>
</tbody>
</table>
## Glossary

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer survivors</td>
<td>A population with a history of a cancer diagnosis, referring to individuals who have completed treatment for active cancer, who have metastatic disease, or who require intermittent treatment.</td>
</tr>
<tr>
<td>EHR problem list</td>
<td>A list used within electronic health records (EHR) that outlines the illnesses, injuries, and other factors affecting the health of a patient, usually identifying symptoms, time of occurrence, diagnosis, and treatment or resolution.</td>
</tr>
<tr>
<td>Electronic nicotine delivery systems (ENDS)</td>
<td>Electronic nicotine delivery systems (ENDS) represent a rapidly changing class of tobacco products known by many different names, including e-cigarettes, e-cigs, vapes, mods, and tank systems. ENDS deliver an aerosol to the user that typically contains nicotine, propylene glycol, vegetable glycerin, and flavoring chemicals.</td>
</tr>
<tr>
<td>Long-term abstinence</td>
<td>Typically refers to 6 or more months without tobacco product use.</td>
</tr>
<tr>
<td>Medically underserved and vulnerable populations</td>
<td>Populations who experience disparities in cancer burden, smoking prevalence, access to smoking cessation treatment, and/or smoking cessation treatment success. For the purposes of this monograph, ‘vulnerable’ refers to a heightened risk for cancer or a higher cancer burden relative to the general population. Medically underserved and vulnerable populations discussed in this monograph include socioeconomically disadvantaged populations, racial and ethnic minority populations, rural populations, sexual and gender minority (SGM) populations, individuals with co-occurring substance use disorders, and individuals with serious mental illness (SMI).</td>
</tr>
<tr>
<td>Pack year</td>
<td>A way to measure the amount a person has smoked over a period of time. It is calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked. For example, 1 pack year is equal to smoking 1 pack per day for 1 year, or 2 packs per day for half a year.</td>
</tr>
<tr>
<td>Patients with cancer</td>
<td>Refers to those newly diagnosed with cancer and in treatment for active or recurrent cancer.</td>
</tr>
<tr>
<td>Smoking</td>
<td>Refers to cigarette use.</td>
</tr>
<tr>
<td>Smoking cessation treatment</td>
<td>Encompasses treatment aimed at smoking reduction, smoking cessation, and relapse prevention after treatment.</td>
</tr>
<tr>
<td>Tobacco use</td>
<td>Refers to use of tobacco products including cigarettes, cigars, hookah, ENDS, and smokeless tobacco.</td>
</tr>
</tbody>
</table>